NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00417911,Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients,https://clinicaltrials.gov/study/NCT00417911,,COMPLETED,"Multiple myeloma is a malignant incurable hematological disease where survival has been significantly improved by high-dose melphalan with autologous stem cell support (ASCT) in younger patients. However, the disease will eventually relapse and new treatment is demanded. Bortezomib is a newly approved drug for treating relapsing multiple myeloma. It has a different biological effect and response even in patients refractory to conventional chemotherapy. The purpose of the study is in a randomized design to investigate if addition of bortezomib by 20 injections during a 4 months period starting 3 month after ASCT can prolong the time to progression compared to patients receiving no consolidation or maintenance therapy.",NO,Multiple Myeloma,DRUG: bortezomib,"Evaluate the effect on EFS (an event is defined as either progression or death of any cause without preceding progression) of consolidation treatment with bortezomib after ASCT compared to no consolidation, 1 year after randomization of the last patient",Overall survival from ASCT|Overall survival from start of relapse treatment|Time to need for relapse treatment|Response rate in patients not in CR following ASCT|Toxicity from consolidation treatment|Quality of life|Cost utility|Planned subgroup analysis: comparison of primary and secondary endpoint in patients receiving one vs. two high dose treatments,,Nordic Myeloma Study Group,Janssen-Cilag Ltd.,ALL,"ADULT, OLDER_ADULT",PHASE3,400,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,NMSG 15/05|EudraCT No: 2005-002756-18,2005-12,2009-05,2010-05,2007-01-04,,2010-06-22,"Hæmatologisk afdeling L Amtssygehuset i Herlev, Herlev, DK-2730, Denmark|Medicinsk Hæmatologisk afd L4042, Rigshospitalet, København Ø, DK-2100, Denmark|Hæmatologisk afd X, Odense Universitetshospital, Odense C, DK-5000, Denmark|Hæmatologisk afdeling B, Aalborg Sygehus Syd, Ålborg, DK-9000, Denmark|Hæmatologisk afd. B, Århus Universitetshospital, Amtssygehuset, Århus C, DK-8000, Denmark|Tampere University Hospital, Dep 10a, Tampere, SF-33 521, Finland|Turku University Hospital, Dept. of Medicine, PL 52,, Turku, SF-20521, Finland|Hemathology department, University State Hospital, Landspitali, Reykjavik, 101, Iceland|Hematologisk seksjon, med avd, Haukeland Universitetssykehus, Bergen, N-5021, Norway|Seksjon for blodsykdommer, Med. avd.,Rikshospitalet, Oslo, N - 0027, Norway|Hematologisk avdeling Ullevål Sykehus, Oslo, N - 0407, Norway|Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge, Tromsø, N-9038, Norway|Hematologisk seksjon Regionssykehuset, Trondheim, N - 7006, Norway|Hematologiska klin, Huddinge sjukhus, Huddinge, SE-141 86, Sweden|Hematologkliniken, Universitetssjukhuset, Linköping, SE-581 85, Sweden|University Hospital Lund, Lund, SE-221 85, Sweden|Medicinklin, Universitetssjukhuset MAS,, Malmö, SE-205 02, Sweden|Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus, Umeå, SE-901 85, Sweden|Medicinklin, Akademiska sjukhuset, Uppsala, SE-751 85, Sweden|Medicinkliniken, Universitetssjukhuset, Örebro, SE-70185, Sweden",
